title: The influence of intraoperative pleural perfusion with matrine-cisplatin or cisplatin on stromal cell-derived factor-1 in non-small cell lung cancer patients with subclinical pleural metastasis.
abstract: The early diagnosis and treatment of non-small cell lung cancer (NSCLC) in patients with subclinical pleural metastasis is currently a challenge. In an effort to establish a method for the diagnosis and treatment of these patients, we conducted a single-blind study during which intraoperative pleural lavage cytology (PLC) was performed in 164 patients with NSCLC without obvious pleural effusion. Stromal cell-derived factor-1 (SDF-1) serum concentrations were analyzed using enzyme-linked immunoassay on day 1 prior to tumor resection and on day 7 postoperatively. Western blot analysis was used for the detection of CXCR4 protein expression in resected tumors. Intraoperative pleural perfusion chemotherapy, with either cisplatin or cisplatin plus matrine, was given to patients with positive PLC. A group of 30 patients with NSCLC that did not undergo intraoperative PLC were used as a control group. Of the 164 study patients, 41 (25%) patients had positive PLC. Serum SDF-1 concentrations were higher in PLC-positive patients compared with patients negative for PLC and control patients. Serum SDF-1 concentrations were also lower at postoperative day 7 in patients treated with cisplatin plus matrine compared with control patients and those perfused with cisplatin alone. A lower incidence of chemotherapy-related adverse events was observed in patients treated with cisplatin plus matrine versus those treated with cisplatin alone during the first postoperative month. Patients with positive PLC showed a higher CXCR4 protein expression than patients with negative PLC. Based on the results of this study, PLC combined with serum SDF-1 concentration measurements may be considered as an effective index to determine the risk of subclinical pleural metastasis in patients with lung cancer. In addition, cisplatin plus matrine was confirmed as an initial approach for pleural perfusion and was superior to cisplatin alone.
authors.affiliation: The First Affiliated Hospital, Liaoning University of Chinese Traditional Medicine, No. 79 of Chongshan Eastern Road, 110032 Huanggu District, Shenyang, Liaoning Province, China. yangliang_0927@163.com
authors.forename: Cheng-Liang
authors.initials: CL
authors.lastname: Yang
authors.forename: Shun-Shou
authors.initials: SS
authors.lastname: Liu
authors.forename: Ye-Gang
authors.initials: YG
authors.lastname: Ma
authors.forename: Yong-Yu
authors.initials: YY
authors.lastname: Liu
authors.forename: Yi-Xue
authors.initials: YX
authors.lastname: Xue
authors.forename: Bo
authors.initials: B
authors.lastname: Huang
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000627:therapeutic use*; D000871:Anthelmintics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D015153:Blotting, Western; D018196:Carcinoma, Adenosquamous / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D018287:Carcinoma, Large Cell / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D016022:Case-Control Studies; D054377:Chemokine CXCL12 / Q000378:metabolism*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007430:Intraoperative Care; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010997:Pleural Neoplasms / Q000378:metabolism* / Q000556:secondary / Q000628:therapy; D011379:Prognosis; D011807:Quinolizines / Q000627:therapeutic use*; D016037:Single-Blind Method; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000871:Anthelmintics; D000970:Antineoplastic Agents; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D011807:Quinolizines; D002945:Cisplatin; D000093842:Matrines